Thrombologic ApS Report issue

For profit Phase 2
Founded: Copenhagen Denmark (2009)
Status: Defunct (2017)

Organization Overview

First Clinical Trial
2010
NCT01179776
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (3)

enoxaparin (lovenox) (1 trial)

eptifibatide (integrilin) (1 trial)

iloprost (ventavis) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Infarction (Phase 2)

Myocardial Infarction (Phase 2)

Pneumonia (Phase 2)

Sepsis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3